UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$498M |
| 2 |
Ametek
AME
|
+$445M |
| 3 |
Microsoft
MSFT
|
+$432M |
| 4 |
Apple
AAPL
|
+$209M |
| 5 |
Tesla
TSLA
|
+$198M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$759M |
| 2 |
Accenture
ACN
|
+$529M |
| 3 |
ConocoPhillips
COP
|
+$392M |
| 4 |
iShares Core S&P Total US Stock Market ETF
ITOT
|
+$324M |
| 5 |
iShares Core S&P Small-Cap ETF
IJR
|
+$310M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 15.34% |
| 3 | Financials | 12.73% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Industrials | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
HUB Group
HUBG
$2.92B
| $2.7M | ﹤0.01% |
67,888
+2,172
| +3% | +$84.8K |
|
1352
Nurix Therapeutics
NRIX
$2.67B
| $2.7M | ﹤0.01% |
245,496
+14,904
| +6% | +$180K |
|
1353
Red Rock Resorts
RRR
$3.59B
| $2.68M | ﹤0.01% |
67,107
+2,027
| +3% | +$83.2K |
|
1354
International Seaways
INSW
$4.52B
| $2.67M | ﹤0.01% |
72,072
-43,550
| -38% | -$1.76M |
|
1355
Brink's
BCO
$4.57B
| $2.66M | ﹤0.01% |
49,531
+445
| +0.9% | +$25.8K |
|
|
EVA
1356
DELISTED
Enviva Inc.
EVA
| $2.64M | ﹤0.01% |
49,874
+13,278
| +36% | +$759K |
|
1357
Schneider National
SNDR
$6.22B
| $2.64M | ﹤0.01% |
112,772
+5,960
| +6% | +$139K |
|
1358
Corcept Therapeutics
CORT
$12.4B
| $2.64M | ﹤0.01% |
129,904
-3,057
| -2% | -$76.6K |
|
|
PDCO
1359
DELISTED
Patterson Companies, Inc.
PDCO
| $2.62M | ﹤0.01% |
93,539
+11,453
| +14% | +$316K |
|
1360
Itron
ITRI
$4.52B
| $2.61M | ﹤0.01% |
51,479
-102
| -0.2% | -$5.04K |
|
1361
Roivant Sciences
ROIV
$25.9B
| $2.61M | ﹤0.01% |
326,042
+53,493
| +20% | +$298K |
|
1362
J&J Snack Foods
JJSF
$1.68B
| $2.6M | ﹤0.01% |
17,341
| – | – |
|
1363
Northwest Bancshares
NWBI
$2.26B
| $2.6M | ﹤0.01% |
185,623
+30,958
| +20% | +$446K |
|
1364
Marqeta
MQ
$1.64B
| $2.59M | ﹤0.01% |
106,005
-60,786
| -36% | -$1.66M |
|
1365
PTC Therapeutics
PTCT
$6.17B
| $2.59M | ﹤0.01% |
67,869
-194,100
| -74% | -$8.07M |
|
|
AXNX
1366
DELISTED
Axonics, Inc. Common Stock
AXNX
| $2.58M | ﹤0.01% |
41,324
+653
| +2% | +$43.3K |
|
1367
Alight
ALIT
$389M
| $2.58M | ﹤0.01% |
15,412
| – | – |
|
1368
International Bancshares
IBOC
$4.49B
| $2.57M | ﹤0.01% |
56,135
+4,625
| +9% | +$223K |
|
1369
Quaker Houghton
KWR
$2.91B
| $2.57M | ﹤0.01% |
15,379
+1,964
| +15% | +$330K |
|
1370
Graham Holdings Company
GHC
$4.96B
| $2.57M | ﹤0.01% |
4,248
| – | – |
|
1371
WesBanco
WSBC
$3.99B
| $2.56M | ﹤0.01% |
69,334
+9,155
| +15% | +$352K |
|
1372
APi Group
APG
$18.3B
| $2.56M | ﹤0.01% |
204,219
+7,836
| +4% | +$90.5K |
|
1373
Edgewell Personal Care
EPC
$1.28B
| $2.56M | ﹤0.01% |
66,348
-2,796
| -4% | -$111K |
|
|
ISEE
1374
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.56M | ﹤0.01% |
119,397
+8,590
| +8% | +$183K |
|
1375
TripAdvisor
TRIP
$1.26B
| $2.55M | ﹤0.01% |
141,988
+16,719
| +13% | +$349K |
|
Similar funds
UBS AM's Q4 2022 Portfolio in Review
As of Q4 2022, UBS AM held 2,824 positions worth $191B, up 7% from $178B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
UBS AM's Q4 2022 filing shows 88 new, 1,334 increased, 722 reduced and 301 closed positions. Its largest new stake was Ferguson: 543,379 shares worth $69M. The largest sale was Amgen, an estimated $759M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q4 2022 buy was Ferguson: 543,379 shares worth $69M.
- UBS AM added most to Amazon in Q4 2022, an estimated $498M increase.
- UBS AM's biggest Q4 2022 reduction was Accenture, cutting an estimated $529M.
- UBS AM fully exited Amgen in Q4 2022, selling an estimated $759M.
- UBS AM's ten largest holdings make up 19% of its $191B portfolio in Q4 2022.
- UBS AM opened 88 new positions and closed 301 in Q4 2022.
- UBS AM's portfolio value rose 7% quarter-over-quarter to $191B.
Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.